Meeting
2022 ASCO Annual Meeting
Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors.
Authors
Alexander Starodub
The Christ Hospital, Cincinnati, OH
Alexander Starodub , Ashwin Gollerkeri , Chris De savi , Joyoti Dey , Sagar Agarwal , Sean Donohue , Rachelle Perea , Christine Klaus , Jared Gollob
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT05225584
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3171)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3171
Abstract #
TPS3171
Poster Bd #
152b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2017 ASCO Annual Meeting
Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma.
First Author: David Stephen Shulman
Poster
2016 ASCO Annual Meeting
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314).
First Author: Eric Schafer
Poster
2015 ASCO Annual Meeting
Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study.
First Author: Robin Elizabeth Norris